Infliximab for vascular involvement in Behçet's syndrome

Hatemi, Gülen; Tukek, Nur Beyza; Esatoğlu, Sinem Nihal; Özgüler, Yeşim; Taflan, S. S.; Uygunoğlu, Uğur; Melikoğlu, Melike; Uğurlu, Serdal; Fresko, İzzet; Síva, Aksel; Kutlubay, Zekayі; Yurdakul, Sebahattin; Yazıcı, Hasan; Hamuryudan, Vedat

doi:10.1016/j.clim.2023.109682

Cited by 7 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the unique role of TNFα in BD, 25 anti-TNFα agents have been employed in the treatment of refractory BD, including conditions like neuro-Behcet's disease and vascular involvement in Behcet's syndrome, and have demonstrated effectiveness. 26,27 In addition, there is evidence that anti-TNFα agents have beneficial effects other rheumatic diseases such as ankylosing spondylitis (AS), rheumatoid arthritis (RA), and psoriatic arthritis (PsA). [28][29][30] Usually, patients with BU exhibit significantly higher levels of TNFα in their serum and eyes compared to those with other causes of uveitis.…”

Section: Discussionmentioning

confidence: 99%

Long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis

Guan,

Zhao,

Xin

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimThis study aims to evaluate the long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha (anti‐TNF‐α) therapy for patients with Behcet's uveitis (BU) using meta‐analysis.MethodsWe searched the Web of Science and PubMed databases for eligible studies up to December 1, 2022. The quality of each identified study was assessed using the Joanna Briggs Institute's case series literature quality assessment tool. Statistical analysis was conducted using Stata 16.0 software with a random‐effects model.ResultsTwelve studies comprising 1156 patients with BU were included in our analysis. We found that 85.0% of patients achieved ocular inflammation remission after receiving anti‐TNF‐α treatment, with a 95% confidence interval (CI) ranging from 78.7% to 90.5%. Additionally, 77.4% (95% CI: 57.5%–92.5%) experienced an improvement in visual acuity (VA). Moreover, the pooled dose reduction of glucocorticoids (GCs) was 11.08 mg (95% CI: −13.34 mg to −8.83 mg). Throughout the follow‐up period, the cumulative retention rate of the medication was 67.3% (95% CI: 53.7%–79.6%). Serious adverse events occurred in 5.8% (95% CI: 3.1%–8.9%) of cases, with the three most common types being severe infusion or injection reactions (2.7%; 95% CI: 0.8%–5.4%), tuberculosis (1.3%; 95% CI: 0.0%–3.9%), and bacterial pneumonia (1.3%; 95% CI: 0.1%–3.4%). Subgroup analysis revealed that ocular inflammation remission rates were 89.3% (95% CI: 81.2%–95.5%) for adalimumab treatment and 83.7% (95% CI: 75.3%–90.8%) for infliximab treatment. The drug retention rate after adalimumab therapy was 70.3% (95% CI: 62.0%–78.0%) compared to 66.4% (95% CI: 48.6%–82.2%) for infliximab treatment. Furthermore, the incidence of severe infusion or injection reactions was 2.2% (95% CI: 0.1%–5.8%) following adalimumab treatment and 3.5% (95% CI: 0.7%–7.7%) following infliximab treatment.ConclusionsAnti‐TNF‐α therapy represents an effective treatment for BU patients with favorable safety profile and high drug retention rate and a potential advantage of adalimumab over infliximab in terms of ocular inflammation remission, drug retention, and the incidence of severe infusion or injection reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis

Guan,

Zhao,

Xin

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

Disease and Treatment-Specific Complications of Behçet Syndrome

Esatoglu,

Ozguler,

Hatemi

2023

Curr Rheumatol Rep

View full text Add to dashboard Cite

Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance

Hibi,

Hirohata,

Hisamatsu

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Behçet’s disease (BD) with intestinal, neurological (NBD), and vascular (VBD) manifestations often leads to poor outcomes. Infliximab is approved for the treatment of intestinal BD, NBD, and VBD in Japan; however, evidence regarding its safety and effectiveness in these patients is limited. We conducted a 2-year post-marketing surveillance to evaluate the safety and effectiveness of infliximab in patients with intestinal BD, NBD, and VBD in Japan. Methods This 2-year, multicenter, prospective, observational study included all patients with intestinal BD, NBD, or VBD, who had experienced an insufficient response to conventional therapies (e.g., glucocorticoids and immunosuppressants/immunomodulators), and initiated infliximab for the first time at participating medical institutions. The safety endpoints included adverse events and adverse drug reactions (ADRs), and the effectiveness endpoints included global improvement, and for patients with acute NBD, acute attacks. Results Between October 2015 and August 2018, 255 patients (171 intestinal BD, 49 NBD, and 51 VBD; including 16 with two disease types) were enrolled from 133 medical centers and treated with infliximab. Adverse events, ADRs, and serious ADRs occurred in 100 (39.2%), 72 (28.2%), and 38 (14.9%) patients, respectively; incidences were generally similar across intestinal BD, NBD, and VBD groups. No new safety concerns were identified. At the final evaluation, 68.8% of patients with intestinal BD showed improvement, most patients with chronic progressive NBD and VBD had not worsened (100% and 91.7%, respectively), and 93.3% of patients with acute NBD had no new acute attacks during the observation period. Conclusion These results confirmed the safety and effectiveness of infliximab in clinical practice in 255 patients with intestinal BD, NBD, and VBD. There were no new safety concerns. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-024-02993-9.

show abstract

Infliximab for vascular involvement in Behçet's syndrome

Cited by 7 publications

References 26 publications

Long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis

Long‐term efficacy, safety, and cumulative retention rate of antitumor necrosis factor‐alpha treatment for patients with Behcet's uveitis: A systematic review and meta‐analysis

Disease and Treatment-Specific Complications of Behçet Syndrome

Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance

Contact Info

Product

Resources

About